Detalhe da pesquisa
1.
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.
Blood
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691678
2.
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
N Engl J Med
; 386(1): 11-23, 2022 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34986284
3.
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Br J Haematol
; 193(4): 750-760, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33650100
4.
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
Blood
; 129(9): 1143-1154, 2017 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27872058
5.
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Blood
; 126(3): 291-9, 2015 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25987659
6.
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
BMC Cancer
; 17(1): 852, 2017 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29241450
7.
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
Br J Haematol
; 192(1): e14-e16, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222153
8.
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
Am J Hematol
; 90(1): 42-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25294016
9.
Differential and tumor-specific expression of CD160 in B-cell malignancies.
Blood
; 118(8): 2174-83, 2011 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-21715317
10.
Resolution of dysglycaemia after treatment of monoclonal gammopathy of endocrine significance.
Eur J Endocrinol
; 189(6): K25-K29, 2023 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37818852
11.
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
Lancet Haematol
; 10(2): e93-e106, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36529145
12.
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.
Blood Adv
; 6(7): 2219-2229, 2022 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34933333
13.
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.
Blood Adv
; 6(7): 2207-2218, 2022 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34972214
14.
Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia.
Blood
; 112(3): 814-21, 2008 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18490517
15.
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
J Clin Oncol
; 36(15): 1486-1497, 2018 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29601212
16.
Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology.
Br J Haematol
; 125(5): 576-83, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15147372